---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043924"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:59.494511+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celularity raises FY 2024 net sales guidance to $54-60M; October sales hit record $8.3-8.9M

## Summary
- Raises full-year 2024 expected net sales guidance to $54M-$60M from $50M-$56M, citing strong advanced biomaterial sales.
- Expected net sales through October 31, 2024: $44.4M ($40.2M advanced biomaterials, $4.2M biobanking); includes ~$9M from new Rebound product.
- October 2024 expected net sales of $8.3M-$8.9M marks highest-ever single-month figure.
- Filed Q2 2024 Form 10-Q on Nov 6, resolving Nasdaq non-compliance notice from Oct 16, 2024.
- Advanced biomaterial product sales for first half 2024 exceeded $24M, surpassing full-year 2023 total.

## SEC filing metadata
- accession: 0001493152-24-043924
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315224043924/0001493152-24-043924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315224043924/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043924
- JSON: https://secwatch.observer/filing/0001493152-24-043924.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.